NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News

$29.18

+1.03 (+3.66%)

(As of 06/8/2023 ET)

Compare

Today's Range: $27.35
▼
$29.18
50-Day Range: $19.01
▼
$29.18
52-Week Range: $4.48
▼
$30.30

Volume: 385,419 shs
Average Volume: 290,043 shs
Market Capitalization: $1.54 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.29

MoonLake Immunotherapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 13.3% Downside
$25.29 Price Target
Short Interest: Bearish
13.55% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$11.60 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.00) to ($1.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.02 out of 5 stars

Medical Sector

927th out of 981 stocks

Pharmaceutical Preparations Industry

453rd out of 475 stocks

1.5

Analyst's Opinion

Consensus Rating
MoonLake Immunotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.29, MoonLake Immunotherapeutics has a forecasted downside of 13.3% from its current price of $29.18.
Amount of Analyst Coverage
MoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
13.55% of the float of MoonLake Immunotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
Change versus previous month
Short interest in MoonLake Immunotherapeutics has recently increased by 30.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
MoonLake Immunotherapeutics does not currently pay a dividend.
Dividend Growth
MoonLake Immunotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MLTX.

0.6

News and Social Media Coverage

Search Interest
Only 6 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
4 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MoonLake Immunotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,601,089.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
15.27% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
76.13% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.00) to ($1.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MoonLake Immunotherapeutics is -25.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MoonLake Immunotherapeutics is -25.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MoonLake Immunotherapeutics has a P/B Ratio of 22.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Stock News Headlines

May 30, 2023 | benzinga.com

Thinking about buying stock in Comfort Systems, MoonLake Immunotherapeutics, Limbach, KBR, or Arcosa?

May 27, 2023 | finance.yahoo.com

MLTX - MoonLake Immunotherapeutics

June 8, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 26, 2023 | finance.yahoo.com

MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why

May 26, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $25.29 Average PT from Brokerages

May 18, 2023 | americanbankingnews.com

Critical Survey: MoonLake Immunotherapeutics (MLTX) and Its Competitors

May 18, 2023 | americanbankingnews.com

Equities Analysts Issue Forecasts for MoonLake Immunotherapeutics' Q2 2023 Earnings (NASDAQ:MLTX)

May 17, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 3%

June 8, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Software" to Revolutionize Warfare

This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>

May 17, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics Forecasted to Post FY2023 Earnings of ($0.92) Per Share (NASDAQ:MLTX)

May 17, 2023 | americanbankingnews.com

Q2 2023 Earnings Estimate for MoonLake Immunotherapeutics (NASDAQ:MLTX) Issued By SVB Leerink

May 17, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX) Boosted by HC Wainwright

May 15, 2023 | markets.businessinsider.com

BTIG Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)

May 13, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Reaches New 12-Month High at $29.59

May 12, 2023 | finanznachrichten.de

MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

May 12, 2023 | finance.yahoo.com

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023 | finance.yahoo.com

Why MoonLake (MLTX) Might Surprise This Earnings Season

May 10, 2023 | finance.yahoo.com

Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep going

May 10, 2023 | markets.businessinsider.com

MoonLake Immunotherapeutics (MLTX) Gets a Buy from H.C. Wainwright

May 8, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics' (MLTX) Reiterates Rating Reiterated at 22nd Century Group

May 7, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics to Post Q1 2024 Earnings of ($0.44) Per Share, HC Wainwright Forecasts (NASDAQ:MLTX)

May 5, 2023 | msn.com

HC Wainwright & Co. Reiterates MoonLake Immunotherapeutics - (MLTX) Buy Recommendation

May 4, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

May 3, 2023 | finance.yahoo.com

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

May 3, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up to $21.30

May 3, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $25.29 Average Target Price from Analysts

May 2, 2023 | msn.com

Guggenheim Initiates Coverage of MoonLake Immunotherapeutics - (MLTX) with Buy Recommendation

See More Headlines

MLTX Price History

30 days | 90 days | 365 days | Advanced Chart

MLTX Company Calendar

Last Earnings: 3/20/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MLTX
CUSIP: N/A
CIK: 1821586
Web: www.moonlaketx.com
Phone: 41-41-510-8022
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.29
High Stock Price Forecast: $36.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: -13.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -56.52%
Return on Assets: -52.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.14
Quick Ratio: 9.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: 22.45

Miscellaneous

Outstanding Shares: 52,700,000
Free Float: 44,654,000
Market Cap: $1.54 billion
Optionable: Not Optionable
Beta: 0.93

Key Executives

Dr. Jorge Santos da Silva (Age 45)
Co-Founder, CEO & Director
Comp: $460.29k

Dr. Kristian Reich (Age 57)
Co-Founder & Chief Scientific Officer
Comp: $489.9k

Mr. Matthias Bodenstedt (Age 35)
Chief Financial Officer
Comp: $324.91k

Mr. Oliver Daltrop
Chief Technical Officer

Nicolas Mosimann
Gen. Counsel

Annett Zippel
Director of People & Culture

Ms. Nuala Brennan
Chief Clinical Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MLTX Stock - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MLTX shares.
View MLTX analyst ratings or view top-rated stocks.
What is MoonLake Immunotherapeutics' stock price forecast for 2023?: 11 Wall Street analysts have issued twelve-month price objectives for MoonLake Immunotherapeutics' stock. Their MLTX share price forecasts range from $16.00 to $36.00. On average, they predict the company's share price to reach $25.29 in the next twelve months. This suggests that the stock has a possible downside of 13.3%.
View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts.
How have MLTX shares performed in 2023?: MoonLake Immunotherapeutics' stock was trading at $10.50 on January 1st, 2023. Since then, MLTX stock has increased by 177.9% and is now trading at $29.18.
View the best growth stocks for 2023 here.
Are investors shorting MoonLake Immunotherapeutics?: MoonLake Immunotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,320,000 shares, an increase of 30.1% from the April 30th total of 3,320,000 shares. Based on an average daily volume of 355,000 shares, the days-to-cover ratio is currently 12.2 days. Currently, 13.6% of the company's stock are short sold.
View MoonLake Immunotherapeutics' Short Interest.
When is MoonLake Immunotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our MLTX earnings forecast.
How were MoonLake Immunotherapeutics' earnings last quarter?: MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings data on Monday, March, 20th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02.

What ETFs hold MoonLake Immunotherapeutics' stock?: ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include BlackRock Future Health ETF (BMED) and First Trust IPOX Europe Equity Opportunities ETF (FPXE).
What is MoonLake Immunotherapeutics' stock symbol?: MoonLake Immunotherapeutics trades on the NASDAQ under the ticker symbol "MLTX."
Who are MoonLake Immunotherapeutics' major shareholders?: MoonLake Immunotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.58%), Federated Hermes Inc. (1.53%), FMR LLC (0.90%), JPMorgan Chase & Co. (0.58%), AXA S.A. (0.57%) and Great Point Partners LLC (0.53%).
View institutional ownership trends.
How do I buy shares of MoonLake Immunotherapeutics?: Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MoonLake Immunotherapeutics' stock price today?: One share of MLTX stock can currently be purchased for approximately $29.18.
How much money does MoonLake Immunotherapeutics make?: MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $1.54 billion. The company earns $-49,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
How can I contact MoonLake Immunotherapeutics?: The official website for the company is www.moonlaketx.com. The company can be reached via phone at 41-41-510-8022 or via email at ir@moonlaketx.com.

This page (NASDAQ:MLTX) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News

MoonLake Immunotherapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MLTX Stock News Headlines

MLTX Price History

MLTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MLTX Stock - Frequently Asked Questions

Overall MarketRank^™